MedTrace Logo

Severe Complications After Gastrectomy for Esophagogastric Junction and Gastric Cancer

NCT03909997 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2019-04-11

No results posted yet for this study

Summary

Gastrectomy is the main treatment for gastric and Siewert type II-III esophagogastric junction (EGJ) cancer. This surgery is associated with significant morbidity. The aim of the present study is to identify the predictors of postoperative morbidity and to evaluate long term survival according to complications. This is a retrospective cohort study.

Conditions

Sponsors & Collaborators

  • Hospital Dr Sotero del Rio

    lead OTHER

Principal Investigators

  • Enrique M Norero, MD · Hospital Sotero Del Rio

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-05
Primary Completion
2021-04-05
Completion
2022-04-05

Countries

  • Chile

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03909997 on ClinicalTrials.gov